Según industria sources on the 24th, empresas including Yoo-Yu Pharmaceutical, Hanall Biopharma, HLB Therapeutics, RudaCure, and PNP Biopharm have entered the race to develop tratamiento de la enfermedad de ojo secos.
Dry eye disease is known to have a very rigorous clinical process and aprobación criteria. Because it is a condition highly sensitive to environmental factors, it involves more variables than other ensayo clínicos, and it también difficult to objectively quantify drug eficacia based on pacientes' subjective responses.
Nevertheless, no nacional company has ever succeeded in developing a new drug for this condition, and with el mercado global de tratamiento de la enfermedad de ojo seco mercado proyectoed to expand to KRW 12 trillion by 2028, active investigación is underway.
Bioventure RudaCure está desarrollando tratamiento de la enfermedad de ojo seco candidato 'RCI001.' Según RudaCure, RCI001 se espera que demonstrate faster secreción lagrimal eficacia and daño corneal recovery compared to commercially available competing drugs, along with superior instillation compliance and seguridad. La empresa anticipates that the drug will show rapid onset of action while significantly reducing efectos secundarios such as elevated presión intraocular.